October 27, 2011

Overweight type 2 diabetics needed for weight loss study

Adult males and females between 31-60 years of age and are overweight, may be able to participate in a study to assess the effects of the medication Detemir on weight, brain function and mood, and on blood vessels and other risk factors for heart disease.

Detemir is insulin that is approved by the food and drug administration (FDA) for treatment of diabetes mellitus. This study will compare how diet and Detemir affect areas of the brain that are involved in food intake and the sense of “pleasure” people get from eating. To participate, you must be overweight, have type 2 diabetes, and taking oral anti-diabetic medication for your diabetes.

If you meet the study eligibility criteria and agree to participate, you must be willing to come to the Vanderbilt Clinical Research Center for 4 overnight stays, 13 clinic visits and 17 interactions with a Registered Dietitian or Nurse over a 26 week period.

The study will include blood work, tests of cardiovascular function, DEXA, PET and MRI scans to measure body composition, measurement of your energy expenditure, and brain activity during visual stimuli. You will be provided with the study drug, menus to follow and some foods to include in your meal planning.

If you are interested in this study, please take the screening survey at https://redcap.vanderbilt.edu/surveys/?s=tn7m4I. You will be contacted by our study coordinator for further directions. You may also contact the study nurse, Antoinette Richardson at m.a.richardson@vanderbilt.edu or  936-5144 .